Teng L H, Lu D H
Department of Pathology, Xuanwu Hospital, Capital Medical University,Beijing 100053, China.
Zhonghua Yi Xue Za Zhi. 2022 May 24;102(19):1411-1416. doi: 10.3760/cma.j.cn112137-20220208-00253.
Glioma is one of the most common central nervous system tumors in children.Increasing studies show that compared with adults, some gliomas in children have unique molecular genetic characteristics and completely different biological behaviors, although they are similar to adults in morphology and nomenclature. Therefore, pediatric glioma is by no means a "miniature version" of adults. In the 5th edition of WHO classification of central nervous system tumors published in the end of 2021, one of the most important revisions is the division of the classification into adult-type and pediatric-type diffuse gliomas, and the latter is further divided into pediatric-type diffuse low-grade gliomas and pediatric-type diffuse high-grade gliomas. In addition to histological morphology and clinical features, the basis of classification includes more molecular features. Therefore, in clinical practice, we need to pay more attention to the significance of molecular pathological diagnosis in the diagnosis and treatment of gliomas in children.
胶质瘤是儿童最常见的中枢神经系统肿瘤之一。越来越多的研究表明，与成人相比，儿童的一些胶质瘤虽然在形态学和命名上与成人相似，但具有独特的分子遗传学特征和完全不同的生物学行为。因此，儿童胶质瘤绝不是成人的“缩小版”。在2021年底发布的世界卫生组织中枢神经系统肿瘤分类第5版中，最重要的修订之一是将分类分为成人型和儿童型弥漫性胶质瘤，后者进一步分为儿童型弥漫性低级别胶质瘤和儿童型弥漫性高级别胶质瘤。除了组织形态学和临床特征外，分类依据还包括更多的分子特征。因此，在临床实践中，我们需要更加重视分子病理诊断在儿童胶质瘤诊疗中的意义。
